<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207012</url>
  </required_header>
  <id_info>
    <org_study_id>CA181-003</org_study_id>
    <nct_id>NCT00207012</nct_id>
  </id_info>
  <brief_title>MAD Refractory: Solid Tumor QD w/o Break</brief_title>
  <official_title>Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing&#xD;
      advanced solid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated, biologically active doses and recommended phase 2 dose(s) of BMS-599-626 when administered as a daily uninterrupted oral dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Best Clinical Response)</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>HER2 or EGFR Expressing Advanced Solid Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-599626</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Available for periodic follow-up&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  ECOG performance status score 0-1&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of a primary malignancy of breast, ovarian, bladder,&#xD;
             gastric, non small cell lung or colon origin&#xD;
&#xD;
          -  Tumor paraffin tissue block or 20-30 unstained slides from tumor issue block must be&#xD;
             provided for biomarker and predictive marker analyses&#xD;
&#xD;
          -  Immuno-histochemistry (IHC) analysis of tumor biopsy demonstrating 1+, 2+ or 3+ HER3&#xD;
             expression or EGFR expression. For patients with breast cancer tumors must be HER2&#xD;
             FISH positive (fluorescence in situ hybridization). This analysis may be performed by&#xD;
             hospital laboratory&#xD;
&#xD;
          -  Evidence (radiographic or tissue confirmation) that the disease is metastatic (locally&#xD;
             advanced disease is allowable only if no surgical or local therapeutic option exists)&#xD;
&#xD;
          -  Disease which has progressed on or following currently available standard therapies or&#xD;
             for which no standard therapy exists. (Prior adjuvant or neoadjuvant therapy is&#xD;
             permitted. Prior investigational agents are permitted)&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
          -  Adequate bone marrow function defined as:&#xD;
&#xD;
          -  absolute neutrophil count (neutrophil and bands)&#xD;
&#xD;
          -  &gt;=1,500 cells/mm3&#xD;
&#xD;
          -  platelet count &gt;=1000,000 cells/mm3&#xD;
&#xD;
          -  hemoglobin &gt;= 9.0 g/dl&#xD;
&#xD;
          -  Adequate hepatic function defined as:&#xD;
&#xD;
          -  total bilirubin &lt;= 1.5 times the institutional upper limits of normal&#xD;
&#xD;
          -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST)&lt;=2.5 times the&#xD;
             institutional upper limit of normal&#xD;
&#xD;
          -  Adequate renal function defined as:&#xD;
&#xD;
          -  serum creatine &lt;=1.5 times the institutional upper normal limit&#xD;
&#xD;
          -  PT-INR/PTT ,=1.5 x upper limit of normal. Prophylactic coumadin is allowed&#xD;
&#xD;
          -  Serum potassium, calcium and magnesium levels within institutional normal limits&#xD;
&#xD;
          -  Prior anticancer chemo-, radio-, hormonal or immunotherapy are allowed. Patients must&#xD;
             have recovered from toxicity due to prior therapy (i.e., toxicity has resolved to&#xD;
             baseline or is deemed irreversible). At least 4 weeks must hav elapsed since the last&#xD;
             chemotherapy (6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin),&#xD;
             immunotherapy or radiotherapy and beginning of protocol therapy. At least 2 weeks must&#xD;
             have elapsed since last anticancer hormonal therapy or &quot;targeted&quot; kinase inhibitor&#xD;
             (e.g. Herceptin)&#xD;
&#xD;
          -  Men and women, ages 18 and above&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study and for at least 3 months after&#xD;
             the study in such a manner that the risk of pregnancy is minimized&#xD;
&#xD;
          -  WOCBP include any female who has experienced menarche and who has not undergone&#xD;
             successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral&#xD;
             oophorectomy) or is not postmenopausal Even women who are using oral, implanted or&#xD;
             injectable contraceptive hormones or mechanical products such as an intrauterine&#xD;
             device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or&#xD;
             practicing abstinence or where partner is sterile (e.g. vasectomy) should be&#xD;
             considered to be of child bearing potential.&#xD;
&#xD;
          -  WOCP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L&#xD;
             or equivalent units of HCG) within 72 hours prior to the start of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for&#xD;
             the entire study period and for at least 3 months after the study&#xD;
&#xD;
          -  WOCBP using a prohibited contraceptive method&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Women with a positive pregnancy test on enrollment or prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Men who are unwilling or unable to use an acceptable method of birth control if their&#xD;
             sexual partners are WOCBP for the entire study period and for at least 3 months after&#xD;
             completion of the study&#xD;
&#xD;
          -  Patients with known brain metastasis. Patients with controlled brain metastasis (no&#xD;
             progression for 60 days following defined treatment and no neurologic signs or&#xD;
             symptoms) will be allowed. Patients with signs or symptoms or suggestive of brain&#xD;
             metastasis are not eligible unless brain metastasis are ruled out by CT or MRI&#xD;
&#xD;
          -  A serious uncontrolled medical disorder or active infection which would impair the&#xD;
             ability of the patient to receive protocol therapy&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
          -  A myocardial infarction within 12 months&#xD;
&#xD;
          -  Uncontrolled angina within 6 months&#xD;
&#xD;
          -  Congestive heart failure within 4 months or left ventricular ejection fraction (LVEF)&#xD;
             below lower limit of normal or below 45%&#xD;
&#xD;
          -  Diagnosed or suspected congenital long QT syndrome&#xD;
&#xD;
          -  Any history of clinically significant ventricular arrhythmias (such as ventricular&#xD;
             tachycardia, ventricular fibrillation, or torsade de pointes). Any patient with a&#xD;
             history of any arrhythmia should be discussed with the bMS Medical Monitor prior to&#xD;
             entry into the study&#xD;
&#xD;
          -  Prolonged QTc interval on pre-entry electrocardiogram (&gt;450 msec)&#xD;
&#xD;
          -  Any history of second or third degree heart block (may be eligible if currently have a&#xD;
             pacemaker)&#xD;
&#xD;
          -  Heart rate &lt;50/minute on pre-entry electrocardiogram&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the understanding or rendering&#xD;
             of informed consent&#xD;
&#xD;
          -  Known allergy to BMS-599626 or related compound&#xD;
&#xD;
          -  Investigational agents during or within 4 weeks prior to the start of protocol therapy&#xD;
&#xD;
          -  Recent anticancer therapy&#xD;
&#xD;
          -  Drugs (or medical condition) that are generally accepted to have a risk of causing&#xD;
             Torsade de Pointes. Patients who have discontinued any of these medications must have&#xD;
             a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever&#xD;
             is greater) prior to the first dose of BMS-599626&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must&#xD;
             not be enrolled into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <disposition_first_submitted>February 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 2, 2010</disposition_first_posted>
  <last_update_submitted>February 27, 2010</last_update_submitted>
  <last_update_submitted_qc>February 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

